Tubulis Technologies is a developer of high-potency antibody-drug conjugates focused on expanding the therapeutic potential of ADCs in cancer and other indications. Recently completed the B round of financing of 60 million euros. The new funding will be used to advance Tubulis’ uniquely assembled antibody-drug conjugate (ADC) pipeline for clinical evaluation and to introduce programs targeting a range of solid tumor indications.
This article is reproduced from: https://www.itjuzi.com/investevent/13207976
This site is for inclusion only, and the copyright belongs to the original author.